See the DrugPatentWatch profile for evkeeza
What is Regeneron’s Evkeeza (tisotumab vedotin)?
Evkeeza is a medicine from Regeneron (Regeneron is most often misspelled for Regeneron/Roche). The product name you may be looking for is Evkeeza (tisotumab vedotin). It is an antibody-drug conjugate designed to treat certain cancers by attaching a targeted antibody to a chemotherapy-like payload that is released inside cancer cells.
What cancers is Evkeeza used for?
The key use depends on the specific approved indication and country. If you tell me your country (US, EU, UK, etc.) or the cancer type you’re asking about, I can narrow the answer to the exact approved use.
How does tisotumab vedotin work?
Tisotumab vedotin targets a cancer-associated protein (commonly described as TROP2) using an antibody. The drug is linked to a cytotoxic agent; after binding, the complex is taken into the cancer cell and the payload can be released to kill the cell.
What are the common side effects people ask about?
Side effects vary by regimen and patient factors, but antibody-drug conjugates commonly cause effects tied to both the antibody target and the released cytotoxic component. Commonly discussed categories include eye-related problems and other chemotherapy-like adverse effects. If you share the indication (and whether you mean clinic use or trials), I can list the most relevant side effects for that setting.
How is Evkeeza given (IV or injections), and how often?
Evkeeza is typically administered by intravenous infusion on a set schedule determined by the approved regimen. The exact frequency and premedication requirements can differ by indication and protocol.
What might affect eligibility (performance status, prior treatments)?
Eligibility usually depends on:
- the specific cancer type and subtype
- prior therapies received
- overall health/performance status
- key lab values and organ function
If you say which cancer and where you are located, I can map this to the kind of criteria commonly used for this drug’s use.
Is Evkeeza comparable to other antibody-drug conjugates?
Evkeeza is part of the broader antibody-drug conjugate class. Whether it’s “better” depends on the tumor marker, line of therapy (first-line vs later), and safety tradeoffs compared with alternatives available in your region.
What is the manufacturer, and is it called “Regeneron” or “Regeneron”?
The company is commonly written as Regeneron in text-entry, but the correct spelling for the major oncology company is Regeneron / Regeneron Pharmaceuticals (and the user question appears to mix spellings). If you want, paste the exact wording you saw (label, ad, prescription, or article link) and I’ll confirm the drug name and company.
Quick clarification so I can answer precisely
When you say “Regeneron evkeeza,” what do you want to know most?
1) approved cancer indication
2) dosing schedule
3) side effects
4) how it works
5) whether it’s available/covered in your country
Also tell me your country (US/EU/UK/etc.) and the cancer type if you have it.